However, as we have alluded to, EZH2 mutations cosegregate with other poor-risk characteristics, such as patient age and an increased likelihood of antecedent myeloid malignancy such as MPN or MDS. This evidence concerns the gene EZH2 and myeloproliferative neoplasm.